articleNature CommunicationsNov 4, 2020GOLD OA

Pan-cancer landscape of homologous recombination deficiency

University Medical Center Utrecht · Oncode Institute · +4 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Homologous recombination deficiency (HRD) results in impaired double strand break repair and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar-based pan-cancer Classifier of HOmologous Recombination Deficiency (CHORD) that can discriminate BRCA1- and BRCA2-subtypes. Analysis of a metastatic (n = 3,504) and primary (n = 1,854) pan-cancer cohort reveals that HRD is most frequent in ovarian and breast cancer, followed by pancreatic and prostate cancer. We identify biallelic inactivation of BRCA1, BRCA2, RAD51C or PALB2 as the most common genetic cause of HRD, with RAD51C and PALB2 inactivation resulting in BRCA2-type HRD. We find that while the specific genetic cause of HRD is…

Citation impact

528
total citations
FWCI
27.86
Percentile
100%
References
42
Citations per year

Authors

4

Topics & keywords

Keywords
  • PALB2
  • Homologous recombination
  • Prostate cancer
  • Loss of heterozygosity
  • Cancer research
  • Carcinogenesis
  • Genetics
  • CHEK2
UN Sustainable Development Goals
  • Reduced inequalities
No related works found for this paper.

Funding